Bottieau E, Clerinx J, Van den Enden E, at al. Infectious mononucleosis-like syndromes in febrile travelers returning from the tropics. J Travel Med. 2006;13:191-197.
Heath CW, Brodsky AL, Potolsky AI. Infectious mononucleosis in a general population. Am J Epidemiol. 1972;95:46-52.
Pereira MS, Blake JM, Macrae AD. EB virus antibody at different ages. Br Med J. 1969;4:526-527.
Niederman JC, Evans AS, Subrahmanyan L, et al. Prevalence, incidence and persistence of EB virus antibody in young adults. N Engl J Med. 1970;282:361-365.
Vetsika EK, Callan M. Infectious mononucleosis and Epstein-Barr virus. Expert Rev Mol Med. 2004;6:1-16.
Rea TD, Russo JE, Katon W, et al. Prospective study of the natural history of infectious mononucleosis caused by Epstein-Barr virus. J Am Board Fam Pract. 2001;14:234-242.
Katz BZ. Update on chronic fatigue syndrome and Epstein-Barr virus. Pediatr Ann. 2002;31:741-744.
Ganzel TM, Goldman JL, Padhya TA. Otolaryngologic clinical patterns in pediatric infectious mononucleosis. Am J Otolaryngol. 1996;17:397-400.
De Paor M, O'Brien K, Fahey T, et al. Antiviral agents for infectious mononucleosis (glandular fever). Cochrane Database Syst Rev. 2016 Dec 8;12:CD011487.
White PD, Thomas JM, Amess J, et al. Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric disorders after glandular fever. Br J Psychiatry. 1998;173:475-481.
1. Lajo A, Borque C, Del Castillo F, et al. Mononucleosis caused by Epstein-Barr virus and cytomegalovirus in children: a comparative study of 124 cases. Pediatr Infect Dis J. 1994;13:56-60.
2. Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000;343:481-492.
3. Bottieau E, Clerinx J, Van den Enden E, at al. Infectious mononucleosis-like syndromes in febrile travelers returning from the tropics. J Travel Med. 2006;13:191-197.
4. Chapman AL, Watkin R, Ellis CJ. Abdominal pain in acute infectious mononucleosis. BMJ. 2002;324:660-661.
5. Auwaerter PG. Infectious mononucleosis in middle age. JAMA. 1999;281:454-459.
6. Drebber U, Kasper HU, Krupacz J, et al. The role of Epstein-Barr virus in acute and chronic hepatitis. J Hepatol. 2006;44:879-885.
7. Doja A, Bitnun A, Ford Jones EL, et al. Pediatric Epstein-Barr virus-associated encephalitis: 10-year review. J Child Neurol. 2006;21:384-391.
8. Connelly KP, DeWitt LD. Neurologic complications of infectious mononucleosis. Pediatr Neurol. 1994;10:181-184.
9. Bolis V, Karadedos C, Chiotis I, et al. Atypical manifestations of Epstein-Barr virus in children: a diagnostic challenge. J Pediatr (Rio J). 2016 Mar-Apr;92(2):113-21.
10. Heath CW, Brodsky AL, Potolsky AI. Infectious mononucleosis in a general population. Am J Epidemiol. 1972;95:46-52.
11. Henke CE, Kurland LT, Elveback LR. Infectious mononucleosis in Rochester, Minnesota, 1950 through 1969. Am J Epidemiol. 1973;98:483-490.
12. Visser E, Milne D, Collacott I, et al. The epidemiology of infectious mononucleosis in Northern Scotland: a decreasing incidence and winter peak. BMC Infect Dis. 2014 Mar 20;14:151.
13. Pariente M, Bartolome J, Lorente S, et al. Age distribution of serological profiles of Epstein-Barr virus infection: review of results from a diagnostic laboratory [in Spanish]. Enferm Infecc Microbiol Clin. 2007;25:108-110.
14. Ternak G, Uj M, Szucs G, et al. Sero-epidemiologic study of Epstein-Barr virus markers in patients without mononucleosis at a department for infectious diseases. Orv Hetil. 1995;136:2727-2730.
15. Pereira MS, Blake JM, Macrae AD. EB virus antibody at different ages. Br Med J. 1969;4:526-527.
16. Dowd JB, Palermo T, Brite J, et al. Seroprevalence of Epstein-Barr virus infection in U.S. children ages 6-19, 2003-2010. PLoS One. 2013 May 22;8(5):e64921.
17. Schuster V, Kreth HW. Epstein-Barr virus infection and associated diseases in children. I. Pathogenesis, epidemiology and clinical aspects. Eur J Pediatr. 1992;151:718-725.
18. Crawford DH, Macsween KF, Higgins CD, et al. A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clin Infect Dis. 2006;43:276-282.
19. Niederman JC, Evans AS, Subrahmanyan L, et al. Prevalence, incidence and persistence of EB virus antibody in young adults. N Engl J Med. 1970;282:361-365.
20. Takeuchi K, Tanaka-Taya K, Kazuyama Y, et al. Prevalence of Epstein Barr virus in Japan: trends and future prediction. Pathol Int. 2006;56:112-116.
21. Gershburg E, Pagano JS. Epstein-Barr virus infections: prospects for treatment. J Antimicrob Chemother. 2005;56:277-281.
22. Naito T, Kudo N, Inui A, et al. Causes of infectious mononucleosis-like syndrome in adult patients. Intern Med. 2006;45:833-834.
23. Hurt C, Tammaro D. Diagnostic evaluation of mononucleosis-like illness. Am J Med. 2007;120:e1-e8.
24. Fafi-Kremer S, Morand P, Brion JP, et al. Long-term shedding of infectious Epstein-Barr virus after infectious mononucleosis. J Infect Dis. 2005;191:985-989.
25. Yao QY, Rickinson AB, Epstein MA. A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int J Cancer. 1985;35:35-42.
26. Higgins CD, Swerdlow AJ, Macsween KF, et al. A study of risk factors for acquisition of Epstein-Barr virus and its subtypes. J Infect Dis. 2007;195:474-482.
27. Thomas R, Macsween KF, McAulay K, et al. Evidence of shared Epstein-Barr viral isolates between sexual partners, and low level EBV in genital secretions. J Med Virol. 2006;78:1204-1209.
28. Woodman CB, Collins SI, Vavrusova N, et al. Role of sexual behavior in the acquisition of asymptomatic Epstein-Barr virus infection: a longitudinal study. Pediatr Infect Dis J. 2005;24:498-502.
29. Vetsika EK, Callan M. Infectious mononucleosis and Epstein-Barr virus. Expert Rev Mol Med. 2004;6:1-16.
30. Abbott RJ, Pachnio A, Pedroza-Pacheco I, et al. Asymptomatic primary infection with Epstein-Barr virus: observations on young adult cases. J Virol. 2017 Oct 13;91(21).
31. Ebell MH. Epstein-Barr virus infectious mononucleosis. Am Fam Physician. 2004;70:1279-1287.
32. Ebell MH, Call M, Shinholser J, et al. Does this patient have infectious mononucleosis?: the rational clinical examination systematic review. JAMA. 2016;315:1502-1509.
33. Bruu AL, Hjetland R, Holter E, et al. Evaluation of 12 commercial tests for detection of Epstein-Barr virus-specific and heterophile antibodies. Clin Diagn Lab Immunol. 2000;7:451-456.
34. Bell AT, Fortune B, Sheeler R. Clinical inquiries. What test is the best for diagnosing infectious mononucleosis? J Fam Pract. 2006;55:799-802.
35. Hess RD. Routine Epstein-Barr virus diagnostics from the laboratory perspective: still challenging after 35 years. J Clin Microbiol. 2004;42:3381-3387.
36. Smellie WSA, Forth J, Smart SRS, et al. Best practice in primary care pathology: review 7. J Clin Pathol. 2007;60:458-465.
37. Vouloumanou EK, Rafailidis PI, Falagas ME. Current diagnosis and management of infectious mononucleosis. Curr Opin Hematol. 2012;19:14-20.
38. Auwaerter PG. Recent advances in the understanding of infectious mononucleosis: are prospects improved for treatment or control? Expert Rev Anti Infect Ther. 2006;4:1039-1049.
39. Kofteridis DP, Koulentaki M, Valachis A, et al. Epstein Barr virus hepatitis. Eur J Intern Med, 2011;22:73-76.
40. Rea TD, Russo JE, Katon W, et al. Prospective study of the natural history of infectious mononucleosis caused by Epstein-Barr virus. J Am Board Fam Pract. 2001;14:234-242.
41. Katz BZ. Update on chronic fatigue syndrome and Epstein-Barr virus. Pediatr Ann. 2002;31:741-744.
42. Baron EJ, Miller JM, Weinstein MP, et al. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). Clin Infect Dis. 2013;57:e22-e121.
43. Jiang SY, Yang JW, Shao JB, et al. Real-time polymerase chain reaction for diagnosing infectious mononucleosis in pediatric patients: a systematic review and meta-analysis. J Med Virol. 2016 May;88(5):871-6.
44. Bauer CC, Aberle SW, Popow-Kraupp T, et al. Serum Epstein-Barr virus DNA load in primary Epstein-Barr virus infection. J Med Virol. 2005;75:54-58.
45. Merriam SC, Keeling RP. Beta-hemolytic streptococcal pharyngitis: uncommon in infectious mononucleosis. South Med J. 1983;76:575-576.
46. Hoagland RJ. Infectious mononucleosis. Prim Care. 1975;2:295-307.
47. Torre D, Tambini R. Acyclovir for treatment of infectious mononucleosis: a meta-analysis. Scand J Infect Dis. 1999;31:543-547.
48. Ganzel TM, Goldman JL, Padhya TA. Otolaryngologic clinical patterns in pediatric infectious mononucleosis. Am J Otolaryngol. 1996;17:397-400.
49. Leach TC, Sumaya CV. Epstein-Barr virus. In: Feigin RD, Cherry J, Demmel G, et al., eds. Textbook of pediatric infectious diseases. 5th ed. Philadelphia, PA: WB Saunders; 2003:1932-1948.
50. Walter RB, Hong TC, Bachli EB. Life-threatening thrombocytopenia associated with acute Epstein-Barr virus infection in an older adult. Ann Hematol. 2002;81:672-675.
51. Roy M, Bailey B, Amre DK, et al. Dexamethasone for the treatment of sore throat in children with suspected infectious mononucleosis: a randomized, double-blind, placebo-controlled, clinical trial. Arch Pediatr Adolesc Med. 2004;158:250-254.
52. Rezk E, Nofal YH, Hamzeh A, et al. Steroids for symptom control in infectious mononucleosis. Cochrane Database Syst Rev. 2015;(11):CD004402.
53. Webster J, Osborne S, Rickard CM, et al. Clinically-indicated replacement versus routine replacement of peripheral venous catheters. Cochrane Database Syst Rev. 2015 Aug 14;(8):CD007798.
54. Cyran EM, Rowe JM, Bloom RE. Intravenous gammaglobulin treatment for immune thrombocytopenia associated with infectious mononucleosis. Am J Hematol. 1991;38:124-129.
55. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168-186.
56. Ma C, Wong KC, Wong BCK, et al. Cytokine responses in a severe case of glandular fever treated successfully with foscarnet combined with prednisolone and intravenous immunoglobulin. J Med Virol. 2009;81:99-105.
57. Balfour HH, Hokanson KM, Schacherer RM, et al. A virologic pilot study of valacyclovir in infectious mononucleosis. J Clin Virol. 2007;39:16-21.
58. Adams LA, Deboer B, Jeffrey G, et al. Gancyclovir and the treatment of Epstein-Barr virus hepatitis. J Gastroenterol Hepatol. 2006;21:1758-1760.
59. Yager JE, Magaret AS,3, Kuntz SR, et al. Valganciclovir for the suppression of Epstein-Barr virus replication. J Infect Dis. 2017 Jul 15;216(2):198-202.
60. Milone MC, Tsai DE, Hodinka RL, et al. Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell directed therapy. Blood. 2005;105:994-996.
61. De Paor M, O'Brien K, Fahey T, et al. Antiviral agents for infectious mononucleosis (glandular fever). Cochrane Database Syst Rev. 2016 Dec 8;12:CD011487.
62. Rafailidis PIM. Antiviral treatment for severe EBV infections in apparently immunocompetent patients. J Clin Virol. 2010;49:151-157.
63. Zhang L, Goudth J, Christmas D, et al. Microbial infections in eight genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). J Clin Pathol. 2010;63:156-164.
64. Lerner AM, Beqaj SH, Deeter RG, et al. Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome: thirty-six months follow-up. In Vivo. 2007;21:707-713.
65. Kogelnik AM, Loomis K, Hoegh-Peterson M, et al. Use of valganciclovir with elevated antibody titers against Human herpesvirus-6 (HHV-6) and Epstein-Barr virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue. J Clin Virol. 2006;37(suppl 1):S33-S38.
66. Hickie I, Davenport T, Wakefield D, et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ. 2006;333:575.
67. Nyland M, Naess H, Birkeland JS, et al. Longitudinal follow-up of employment status in patients with chronic fatigue syndrome after mononucleosis. BMJ Open. 2014;4:e005798.
68. Thompson DF, Ramos CL. Antibiotic-induced rash in patients with infectious mononucleosis. Ann Pharmacother. 2017 Feb;51(2):154-162.
69. Farley DR, Zietlow SP, Bannon MP, et al. Spontaneous rupture of the spleen due to infectious mononucleosis. Mayo Clin Proc. 1992;67:846-853.
70. Bartlett A, Williams R, Hilton M. Splenic rupture in infectious mononucleosis: a systematic review of published case reports. Injury. 2016 Mar;47(3):531-8.
71. Stephenson JT, DuBois JJ. Nonoperative management of spontaneous splenic rupture in infectious mononucleosis: a case report and review of the literature. Pediatrics. 2007;120:e432-e435.
72. Heo DH, Baek DY, Oh SM, et al. Splenic infarction associated with acute infectious mononucleosis due to Epstein-Barr virus infection. J Med Virol. 2017 Feb;89(2):332-336.
73. Ali K, Lawthom C. Epstein-Barr virus-associated cerebellar ataxia. BMJ Case Rep. 2013;2013.
74. Kimura H, Hoshino Y, Kanegane H, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood. 2001;15:280-286.
75. Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol. 2006;59:499-503.
76. Sheik-Ali S. Infectious mononucleosis and multiple sclerosis - updated review on associated risk. Mult Scler Relat Disord. 2017 May;14:56-59.
77. Khan G, Hashim MJ. Global burden of deaths from Epstein-Barr virus attributable malignancies 1990-2010. Infect Agent Cancer. 2014 Nov 17;9(1):38.
78. Tao Q, Young LS, Woodman CB, et al. Epstein-Barr virus (EBV) and its associated human cancers - genetics, epigenetics, pathobiology and novel therapeutics. Front Biosci. 2006;11:2672-2713.
79. Green M, Michaels MG. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. Am J Transplant. 2013;13(suppl 3):41-54.
80. Candy B, Chalder T, Cleare AJ, et al. Recovery from infectious mononucleosis: a case for more than symptomatic therapy? A systematic review. Br J Gen Pract. 2002;52:844-851.
81. White PD, Thomas JM, Amess J, et al. Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric disorders after glandular fever. Br J Psychiatry. 1998;173:475-481.
82. Kim A, Yang HR, Moon JS, et al. Epstein-Barr virus infection with acute acalculous cholecystitis. Pediatr Gastroenterol Hepatol Nutr. 2014;17:57-60.
83. Moretti M, Lava SAG, Zgraggen L, et al. Acute kidney injury in symptomatic primary Epstein-Barr virus infectious mononucleosis: systematic review. J Clin Virol. 2017 Jun;91:12-17.
84. Sevier TL. Infectious disease in athletes. Med Clin North Am. 1994;78:389-412.
使用此内容应接受我们的免责声明。
BMJ临床实践的持续改进离不开您的帮助和反馈。如果您发现任何功能问题和内容错误,或您对BMJ临床实践有任何疑问或建议,请您扫描右侧二维码并根据页面指导填写您的反馈和联系信息*。一旦您的建议在我们核实后被采纳,您将会收到一份小礼品。
如果您有紧急问题需要我们帮助,请您联系我们。
邮箱:bmjchina.support@bmj.com
电话:+86 10 64100686-612
*您的联系信息仅会用于我们与您确认反馈信息和礼品事宜。
BMJ临床实践官方反馈平台